Dr. Lal Path Labs Ltd.
NSE: LALPATHLABINE600L01024·HealthcareSmallcap 250·www.lalpathlabs.com ↗·Mcap ₹32,271 Cr·Listed 2015
₹1,952.30▼ ₹9.00  (−0.46%)
52W: ₹1,273 – ₹2,039 · Vol: 4.5L shares · Close 25 Sept
Set Alert
OverviewFinancialsChartsWavesScreenersThesisNewsPeers

News & Filings

NSE filings · newest first · 4 on record

Yesterday

General Updates - Update on acquisition-SHL
M&A / agreementGeneral Updates16:54 IST PDF 324.93 KB XBRL

Fri, 25 Sept, 2026

Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Trading windowTrading Window18:08 IST PDF 307.25 KB XBRL

Thu, 24 Sept, 2026

Acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Subsidiary of the Company
M&A / agreementGeneral Updates17:31 IST PDF 517.32 KB XBRL
Outcome of Board Meeting held on September 24, 2026.
Board outcomeOutcome of Board Meeting17:24 IST PDF 517.32 KB XBRL
Source: NSE corporate announcements, as filed by the company. Times are IST. Press coverage is not included yet.
Filing activity · 30 days
4filings · +4 vs the 30 days before
● Board & AGM 1● Press & deals 2● Regulatory 1
NSE filings by type. Press coverage and sentiment are not included yet.
Material vs routine · 90 days
Material events 3 in 90 days
26 SeptM&A / agreement General Updates - Update on acquisition-SHL PDF
24 SeptM&A / agreement Acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Subsidiary of the Company PDF
24 SeptBoard outcome Outcome of Board Meeting held on September 24, 2026. PDF
Routine disclosures 1
regulatory 1
Split by NSE filing category: business events (results, ratings, deals, leadership, capital actions, regulatory) versus schedules, notices and general updates. Not a view on importance.
Corporate Actions
loading…